|Vuong Trieu PhD, Chairman||Dr. Trieu, an expert in pharmaceutical development, currently serves as Chairman of the Board for Autotelic consortium of companies including Oncotelic, Stocosil, Ithenapharma, Lipomedics, and Autotelic Inc.. Previously he was President and CEO of Igdrasol- developer of 2nd generation Abraxane- where he pioneer the regulatory pathway for approval of paclitaxel nanomedicine through a single bioequivalence trial against Abraxane. When Igdrasol merged with Sorrento Therapeutics, he became CSO and Board Director. At Stocosil he again pioneer the regulatory pathway for taking Olostar, a rosuvastatin/olmesartan FDC into US as an NDA using only Korean data. He was Board Director of Cenomed- a company focusing on CNS drug development. Before that he was Director of Pharmacology, Pharmacokinetics, and Biology at Abraxis where he lead the development of albumin encapsulated therapeutics along building high throughput platform for small molecules, mirRNA, kinases. Prior to that he was Group Leader at Applied Molecular Evoluton where he was developing biobetter for Humira and Enbrel. Before that he was Director of Cardiovascular Biology at Parker Hughes Institute. Dr. Trieu holds a PhD in Microbiology, BS in Microbiology and Botany. He is member of ENDO, ASCO, AACR, and many other professional organization. He is the holder of 28 issued US patents and 69 US patent applications. Dr. Trieu published widely in oncology, cardiovascular, and drug development. His aim is creation of grass root support for personalized drug dosing through therapeutic drug monitoring. Grass root support is being generate through creation of executives/investor through their participation in successful companies under the Autotelic consortium.